Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

246
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
246
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Oncogene·2026
Same author

LLMs for industrial databases: an agro-food production plant use case.

Frontiers in artificial intelligence·2026
Same author

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Nature medicine·2026
Same author

Comparing Clinical Assessments of Pneumonia to Bronchoalveolar Lavage Results in Critically Ill Patients With Suspected Pneumonia.

Annals of the American Thoracic Society·2026
Same author

Optimising time-limited trials in acute respiratory failure: a multicentre focused ethnography protocol.

BMJ open·2025
Same author

ACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer.

Journal of the American College of Radiology : JACR·2025

Related Experiment Video

Updated: Dec 29, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.7K

Biliary tract cancers: systemic therapy for advanced disease.

Francisco J Martinez1, Rachna T Shroff2

  • 1Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ, USA.

Chinese Clinical Oncology
|February 4, 2020
PubMed
Summary

Systemic therapies for biliary tract carcinomas (BTC) are evolving. Gemcitabine plus cisplatin remains standard, with new trials exploring combinations and targeted agents for improved patient survival.

Keywords:
Biliary tract carcinomas (BTC)FOLFOXgemcitabine-cisplatinreviewsystemic therapy

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.8K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K

Related Experiment Videos

Last Updated: Dec 29, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.7K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.8K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.3K

Area of Science:

  • Oncology
  • Medical Oncology
  • Gastrointestinal Oncology

Background:

  • Biliary tract carcinomas (BTC) are frequently diagnosed at advanced stages, necessitating systemic therapy.
  • Limited therapeutic options contribute to a poor prognosis for unresectable BTC.
  • Current treatment paradigms focus on first- and second-line systemic approaches.

Purpose of the Study:

  • To review current and emerging systemic therapies for biliary tract carcinomas.
  • To highlight advancements in first- and second-line treatment strategies.
  • To discuss the potential of novel agents and future directions in BTC management.

Main Methods:

  • Review of clinical trial data and established treatment guidelines for BTC.
  • Analysis of efficacy and survival outcomes for standard chemotherapy regimens.
  • Evaluation of emerging targeted therapies and their role in BTC treatment.

Main Results:

  • Gemcitabine and cisplatin (Gem-Cis) is the current standard first-line chemotherapy.
  • Gem-Cis plus nab-paclitaxel demonstrated improved survival in a Phase II trial.
  • FOLFOX showed a survival benefit in the second-line setting (ABC-06 study).
  • Molecularly targeted agents show promise, with ongoing trials in various lines of therapy.

Conclusions:

  • The combination of Gemcitabine and Cisplatin is the established standard of care for advanced BTC.
  • Ongoing Phase III trials, such as SWOG 1815, may establish new standards of care.
  • Targeted therapies are expanding treatment options for BTC patients, offering a promising future.